Company intelligence / Profile preview
Ukko
Palo Alto, California, United Statesukko.us ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Ukko is developing an investigational therapeutic for peanut allergies and improved gluten for people with gluten sensitivities. The company uses a proprietary AI-driven protein engineering platform to design proteins that don't trigger allergic responses while maintaining their nutritional characteristics.
- Therapeutic areas
- Immunology
- Modalities
- Protein therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ukko.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ukko.